Use of snake venom fractions in the coagulation laboratory

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 5, 1998, Pages 395-404

  Marsh, N A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Clinical applications; Coagulation assays; Haemostasis; Snake venom toxins

Indexed keywords

ACTE; ANCROD; BATROXOBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BOTROCETIN; FIBRINOGEN; FIBROLASE; LUPUS ANTICOAGULANT; PHOSPHOLIPASE A2; PROTAC; PROTEIN C; SNAKE VENOM; TEXTARIN; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; BLOOD CLOTTING; DYSFIBRINOGENEMIA; ENZYME DEGRADATION; FIBRINOLYSIS; HEMOSTASIS; LABORATORY DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; THROMBOCYTE FUNCTION;

EID: 0031820807     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199807000-00001     Document Type: Review

References (119)

1. Kamiguti AS, Hay CRM, Theakston RDG, Zuzel M. Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Toxicon 1996; 34: 627-642.
2. Faiz MA, Falkous G, Harris JB, Mantle D. Comparison of protease and related enzyme activities in snake venoms. Comp Biochem Physiol B 1996; 113: 199-204.
3. Marsh NA. Snake venoms affecting the haemostatic mechanism - a consideration of their mechanisms, practical applications and biological significance. Blood Coag Fibrinol 1994; 5: 399-410.
4. Hutton RA, Warrell DA. Action of snake venom components on the haemostatic system. Blood Rev 1993; 7: 176-189.
5. Markland FS. Snake venoms. Drugs 1997; 54 (suppl 3): 1-10.
6. Marsh NA. Inventory of haemorrhagic factors from snake venoms. Thromb Haemost 1994; 71: 793-797.
7. Pirkle H. Thrombin-like enzymes from snake venoms: an updated inventory. Thromb Haemost 1998; 79: 675-683.
8. Funk C, Gmur J, Herold R, Straub PW. Reptilase-R, a new reagent in blood coagulation. Br J Haematol 1971; 21: 43-52.
9. Howie PW, Prentice CRM, McNicol GP. A method of antithrombin estimation using plasma defibrinated with Ancrod. Br J Haematol 1973; 25: 101-110.
10. Canoso RT, Hutton RA, Deykin D. The haemostatic defect of chronic liver disease. Gastroenterology 1979; 76: 540-547.
11. Latallo Z, Teisseyre E. Evaluation of reptilase-R and thrombin clotting time in the presence of fibrinogen degradation products and heparin. Scand J Haematol 1971; 13 (suppl): 261-266.
12. Matsuda M, Saeki E, Kasamatsu A, Nakamikawa C, Manabe S, Samejima Y. Fibrinogen Kawaguchi: an abnormal fibrinogen characterised by defective release of fibrinopeptide A. Thromb Res 1985; 37: 379-390.
13. Torbet J. Fibrin assembly after fibrinopeptide A release in model systems and human plasma studied with magnetic birefringence. Biochem J 1987: 244: 633-637.
14. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation -evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-721.
15. Carr ME, Carr SL, Greilich PE. Heparin ablates force development during platelet mediated clot retraction. Thromb Haemost 1996; 75: 674-678.
16. Ranby M, Norrman B, Wallen P. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 27: 743-749.
17. Rosing J, Tans G. Structural and functional properties of snake venom prothrombin activators. Toxicon 1992; 30: 1515-1527.
18. Denson KWE, Borrett R, Biggs R. The specific assay of prothrombin using the taipan snake venom. Br J Haematol 1971; 21: 219-226.
19. Kornalik F, Schieck A, Habermann E. Isolation, biochemical and pharmacological characterization of a prothrombin activating principle from Echis carinatus venom. Naunyn Schmiedebergs Arch Pharmacol 1969; 264: 259-260.
20. Kornalik F, Vorlova Z. Ecarin test in diagnosis of dicoumarol therapy, liver diseases and DIC. Folia Haematol (Leipzig), 1988; 115: 483.
21. Weinger RS, Rudy C, Moake JL, Olson JD, Cimo PL. Prothrombin Houston: a dysprothrombin identifiable by crossed immunoelectrofocussing and abnormal Echis carinatus venom activation. Blood 1980; 55: 811-815.
22. Collados MT, Fernandez J, Paramo JA, Montes R, Borbolla JR, Montano LF, et al. Purification and characterization of a variant of human prothrombin - prothrombin Segovia. Thromb Res 1997; 85: 465-477.
23. Sakuragawa N, Takahashi K, Hoshiyama M, Jimbo Ch, Matsuoka M, Ohnishi Y. Significance of a prothrombin assay method using Echis carinatus venom for diagnostic information in disseminated intravascular coagulation syndrome. Thromb Res 1975; 7: 643-653.
24. Novoa E, Seegers WH. Mechanisms of α-thrombin and β-thrombin-E formation: use of ecarin for isolation of meizothrombin 1. Thromb Res 1980; 18: 657-668.
25. Rosing J, Tans G. Meizothrombin, a major product of factor Xa-catalysed prothrombin activation. Thromb Haemost 1988; 60: 355-360.
26. Stevens WK, Cote HCF, MacGillivray RTA, Nesheim ME. Calcium ion modulation of meizothrombin autolysis at Arg55-Asp56 and catalytic activity. J Biol Chem. 1996; 271: 8062-8067.
27. Yamada D, Sekiya F, Morita T. Isolation and characterization of carinactivase, a novel prothrombin activator in Echis carinatus venom with a unique catalytic mechanism. J Biol Chem 1996; 271: 5200-5207.
28. Rosing J, Tans G. Coagulation Factor V: an old star shines again. Thromb Haemost 1997; 78: 427-433.
29. Tokunaga F, Nagasawa K, Tamura S, Miyata T, Iwanaga S, Kisiel W. The factor V-activating enzyme (RVV-V) from Russell's viper venom. J Biol Chem 1988; 263: 17471-17481.
30. Kisiel W, Canfield WM. Snake venom proteases that activate blood coagulation factor V. In: Lorand L (editor). Methods in Enzymology. New York: Academic Press, 1981; 80: 275-285.
31. Keller FG, Ortel TL, Quinn-Allen MA, Kane WH. Thrombin-catalysed activation of recombinant human factor V. Biochemistry 1995; 34: 4118-4124.
32. MacFarlane RG, Barnett B. The haemostatic possibilities of snake venom. Lancet 1934; ii: 985-987.
33. Bachmann F, Duckert F, Koller F. The Stuart-Prower assay and its clinical significance. Thromb Diath Haemorrh 1958; 2: 24.
34. Quick AJ. Thromboplastin generation: effect of the Bell-Alton reagent and Russell's viper venom on prothrombin consumption. Am J Clin Pathol 1971; 55: 555-560.
35. Thiagarajan P, Pengo V, Shapiro SS. The use of dilute Russell viper venom time for the diagnosis of lupus coagulants. Blood 1986; 68: 869-874.
36. Takeya H, Nishida S, Miyata T, Kawada S, Saisaka Y, Morita T, et al. Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. J Biol Chem 1992; 267: 14109-14117.
37. Gowda DC, Jackson CM, Hensley P, Davidson EA. Factor X-activating glycoprotein of Russell's viper venom. J Biol Chem 1994; 269: 10644-10650.
38. Denson KWE. The specific assay of Prower Stuart factor and factor VII. Acta Haematol 1961; 25: 105.
39. Svendsen L, Brogli M, Lindeberg G, Stocker K. Differentiation of thrombin and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitor. Thromb Res 1984; 34: 457-462.
40. Durkee KH, Cheng TM, Doellgast GJ. Enzyme-linked coagulation assay: V. Amplified blotting assays using snake venom conjugates. Analyt Biochem 1990; 184: 375-380.
41. Chattopadhyay A, Fair DS. Molecular recognition in the activation of human blood coagulation factor X. J Biol Chem 1989; 264: 11035-11043.
42. Inoue K, Morita T. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. Eur J Biochem 1993; 218: 153-163.
43. Hardisty RM, Hutton RA. Platelet aggregation and the availability of platelet factor 3. Br J Haematol 1966; 12: 664.
44. Jy WC, Horstman LL, Wang F, Duncan RC, Ahn YS. Platelet factor 3 in plasma fractions - its relation to microparticle size and thromboses. Thromb Res 1995; 80: 471-482.
45. Triplett DA, Brandt JT. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Hematol Pathol 1988; 2: 121-143.
46. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
47. Exner T. Some recent developments with lupus anticoagulants. Blood Coag Fibinol 1994; 5: 281-289.
48. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-1190.
49. Brandt JL, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants - results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost 1995; 74: 1597-1603.
50. Martin BA, Branch DW, Rodgers GM. Sensitivity of the activated partial thromboplastin time, the dilute Russell's viper venom time, and the kaolin clotting time for the detection of the lupus anticoagulant: a direct comparison using plasma dilutions. Blood Coag Fibrinol 1996; 7: 31-38.
51. Joyner KA, Ortel TL. A sensitive DRVVT reagent system for the detection of lupus anticoagulants. Clin Appl Thrombosis/Hemostasis 1995; 1: 73-75.
52. Rooney AM, McNally T, Mackie IJ, Machin SJ. The taipan snake venom time: a new test for lupus anticoagulant. J Clin Pathol 1994; 47: 497-501.
53. Triplett DA, Stocker, Unger GA, Barna LK. The textarin/ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-931.
54. Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for the detection of the lupus anticoagulant. Thromb Haemost 1994; 72: 728-733.
55. McGlasson DL, Babcock JL, Berg L, Triplett DA. Arachnase - an evaluation of a positive control for platelet neutralization procedure testing with seven commercial activated partial thromboplastin time reagents. Am J Clin Pathol 1993; 100: 576-578.
56. Klein JD, Walker FJ. Purification of a protein C activator from the venom of the Southern copperhead (Agkistrodon contortrix contortrix). Biochemistry, 1986; 25: 4175-4179.
57. R from the venom of the southern copperhead (Agkistrodon contortrix). Toxicon 1987; 25: 239-252.
58. Nathan IV, Ping H, Pradhan MM. Protein C functional assay using snake venom activator. Thromb Res 1987; 47: 85-91.
59. R from Agkistrodon contortrix venom. Folia Haematol (Leipzig) 1988; 115: 260-264.
60. R, a novel protein C activator. Thromb Res 1986; 43: 253-264.
61. Takahashi H, Hanano M, Tatewaki W, Shibata A. Fast functional assay of protein C in whole plasma using a snake venom activator: evaluation in patients with congenital and acquired protein C deficiencies. Clin Chim Acta 1988; 175: 217-225.
62. Franchi F, Tripodi A, Valsecchi C, Mannucci PM. Functional assays of protein C: comparison of two snake venom assays with two thrombin assays. Thromb Haemost 1988; 60: 145-147.
63. Robert A, Eschwege V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon contortrix venom (ACVtest): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-566.
64. ++. Br J Haematol 1993; 85: 521-527.
65. Francis RB, Seyfert U. Rapid amidolytic assay of protein C in whole plasma using an activator from the venom of Agkistrodon contortrix. Am J Clin Pathol 1987; 87: 619-625.
66. Suzuki K, Nishioka J. Plasma protein S activity measured using Protac, a snake venom derived activator of protein C. Thromb Res 1988; 49: 241-251.
67. Lee TK, Bangalore N, Velander W, Drohan WN, Lubon H. Activation of recombinant human protein C. Thromb Res 1996; 82: 225-234.
68. Bertina RM, Koelman BPC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
69. Solano C, Hogg AL, Saal RJ, Scott DC, Cobcroft RG. The use of two different APC resistance assay systems provides optimal sensitivity and specificity for diagnosing genetic APC resistance. Blood Coag Fibrinol 1997; 8: 268-273.
70. Hoagland LE, Triplett DA, Peng F, Barna L. APC-resistance as measured by a textarin time assay - comparison to the APTT-based method. Thromb Res 1996; 83: 363-373.
71. Gemmati D, Serino ML, Mari R, Verzola I, Moratelli S, Ballerini G. Different anticoagulant response to activated protein C (APC test) and to Agkistrodon contortrix venom (ACV test) in a family with FV-R506Q substitution. Clin App Thrombosis/Hemostasis 1997; 3: 168-173.
72. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
73. Frosst P, Blom HJ, Goyette P, Sheppard CC, Matthews RG, Boers GJH, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-113.
74. Pecheniuk NM, Marsh NA, Walsh TP, Dale JL. Use of the first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors. Blood Coag Fibrinol 1997; 8: 491-495.
75. Read MS, Potter JY, Brinkhous KM. Venom coagglutinin for detection on von Willebrand factor activity in animal plasmas. J Lab Clin Med 1983; 101: 74-82.
76. Brinkhous KM, Smith SV, Read MS. Botrocetin and von Willebrand factor. In: Pirkle H, Markland FS (editors). Hemostasis and Animal Venoms. New York-Basel: Marcel Dekker Inc., 1988. pp. 377-398.
77. Bloom AL. Progress in the clinical management of haemophilia. Thromb Haemost 1991; 66: 166-177.
78. Miura S, Nishida S, Makita K, Sakurai Y, Shimoyama T, Sugimoto M, et al. Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin. Analyt Biochem 1996; 236: 215-220.
79. Williams SB, McKeown LP, Krutzsch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol 1994; 88: 582-591.
80. Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard M, et al. Von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 1992; 89: 9846-9849.
81. Yoshida E, Fujimura Y, Ikeda Y, Takeda I, Yamamoto Y, Nishikawa K, et al. Impaired high-shear-stress-induced platelet aggregation in patients with chronic renal failure undergoing dialysis. Br J Haematol 1995; 89: 861-867.
82. Ouyang C, Teng CM, Huang TF. Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon 1992; 30: 945-966.
83. Lu X, Rahman S, Deadman JJ, Chino N, Claeson G, Kakkar VV, et al. Natural integrin antagonists from snake venoms: ligand-specific inhibitors. Blood Coag Fibrinol 1993; 4: 361-362.
84. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, et al. Barbourin, a GPIIb/ IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri. J Biol Chem 1991; 266: 9359-9362.
85. Barbouche R, Marrakshi N, Mansuelle P, Krifi M, Fenouillet E, Rochat H, et al. Novel anti-platelet aggregation polypeptides from Vipera lebetina venom - isolation and characterization. FEBS Letters 1996; 392: 6-10.
86. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831-843.
87. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent postangioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17: 89B-95B.
88. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin: a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb/IIIa complex. J Biol Chem 1987; 262: 16157-16163.
89. Huang TF, Wu YJ, Ouyang C. Characterization of a potent platelet aggregation inhibitor from Agkistrodon rhodostoma snake venom. Biochim Biophys Acta 1987; 925: 248-257.
90. Huang TF, Sheu JR, Teng CM. A potent antiplatelet peptide, triflavin from Trimeresurus flavoviridis snake venom. Biochem J 1991; 277: 351-257.
91. Zhou Q, Dangelmaier C, Smith JB. The hemorrhagin catrocollastatin inhibits collagen-induced platelet aggregation by binding to collagen via its disintegrin-like domain. Biochem Biophys Res Commun 1996; 219: 720-726.
92. Liu CZ, Huang TF. Crovidisin, a collagen-binding protein isolated from snake venom of Crotalus viridis, prevents platelet-collagen interaction. Arch Biochem Biophys 1997; 337: 291-299.
93. 1 Biochem Biophys Res Commun 1995; 206: 570-576.
94. Kawasaki T, Fujimura Y, Usami Y, Suzuki M, Miura S, Sakurai Y, et al. Complete aminoacid sequence and identification of the platelet glycoprotein Ib-binding site of jaracaca GPIb-BP, a snake venom protein isolated from Bothrops jaracaca. J Biol Chem 1996; 271: 10635-10639.
95. Marrakchi N, Barbouche R, Bon C, Elayeb M. Cerastatin, a new potent inhibitor of platelet aggregation from the venom of the tunisian viper, Cerastes cerastes. Toxicon 1997; 35: 125-135.
96. Kamiguti AS, Mouradasilva AM, Laing GD, Knapp T, Zuzel M, Crampton JM, et al. Collagen-induced secretion-dependent phase of platelet aggregation is inhibited by the snake venom metalloproteinase jararhagin. Biochim Biophys Acta 1997; 1335: 209-217.
97. 2 of Asian snake venoms. J Toxicol Toxin Rev 1997; 16: 79-113.
98. Kini RM, Evans HJ. Effects of snake venom proteins on blood platelets. Toxicon 1990; 28: 1387-1422.
99. 2 isoenzymes from Naja nigricollis venom. Thromb Res 1989; 55: 481-491.
100. 2 from Naja nigricollis venom inhibits the prothrombinase complex by a novel nonenzymatic mechanism. Biochemistry 1990; 29: 7742-7746.
101. Speijer H, Govers-Riemslag JWP, Zwaal RFA, Rosing J. Platelet procoagulant properties studied with snake venom prothrombm activators. Thromb Haemost 1987; 57: 349-355.
102. 2 isoenzymes from Naja nigricollis venom. Toxicon 1995; 33: 1585-1590.
103. Reid HA, Chan KE. The paradox in therapeutic defibrination. Lancet 1968; I: 485-486.
104. Bell WR. Defibrinogenating enzymes. Drugs 1997; 54: 18-30.
105. Illig KA, Ouriel K. Ancrod: understanding the agent. Sem Vasc Surg 1996; 9: 303-314.
106. Markland FS. Snake venom fibrinogenolytic and fibrinolytic enzymes: an updated inventory. Thromb Haemost 1998; 79: 668-674.
107. Markland FS, Reddy KNN, Guan LF. Purification and characterization of a direct-acting fibrinolytic enzyme from Southern copperhead venom. In: Pirkle H, Markland FS (editors). Hemostasis and Animal Venoms. New York-Basel: Marcel Dekker Inc., 1988. pp. 173-189.
108. Baker BJ, Tu AT. Atroxase: a fibrinolytic enzyme isolated from the venom of western diamondback rattlesnake: isolation, characterization and cloning. Toxicon 1996: 34: 291.
109. Larabadjebari F, Martineauclaire MF, Mauco G, Marchot P. Afaacytin, an ε-β-fibrinogenase from Cerastes cerastes (horned viper) venom, activates purified factor X and induces serotonin release from human blood platelets. Eur J Biochem 1995; 233: 756-765.
110. Gasmi A, Chabchoub A, Guermazi S, Karoui H, Elayeb M, Dellagi K. Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom. Thromb Haemost 1997; 86: 233-242.
111. Sheu JR, Lin CH, Chung JL, Teng CM, Huang TF. Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line. Thromb Res 1992; 66: 679-691.
112. Swaim MW, Chiang HS, Huang TF. Characterization of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin. Eur J Cancer 1996; 32A: 715-721.
113. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin. Breast Cancer Res Treat 1995; 33: 225-235.
114. 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. Br J Cancer 1996; 73: 902-908.
115. Sheu JR, Yen MH, Peng HC, Chang MC, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments. Eur J Pharmacol 1995; 294: 231-238.
116. Sheu JR, Huang TF. Ex-vivo and in-vitro antithrombotic effect of triflavin, an RGD-containing peptide. J Pharm Pharmacol 1994; 46: 58-62.
117. Liu CZ, Peng HC, Huang TF. Crotavirin, a potent platelet aggregation inhibitor purified from the venom of the snake Crotalus viridis. Toxicon 1995; 33: 1289-1298.
118. Markland FS. A snake venom disintegrin prevents reocclusion following thrombolysis in a canine carotid artery thrombosis model and blocks melonoma metastasis. Toxicon 1996 34: 321.
119. 123-disintegrins for imaging thrombi and emboli in a canine model. J Nucl Med 1996; 37: 476-482.